31e Costly Burden of DrugResistant TB Disease in the USverage treatment costs per case 2018 dollarsMultidrugresistant MDR tuberculosis disease is a major health threat globally Nearly half a million ID: 897341
Download Pdf The PPT/PDF document "CDC FACT SHEET" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1 CDC FACT SHEET e Costly Burden of D
CDC FACT SHEET e Costly Burden of Drug-Resistant TB Disease in the U.S. verage treatment costs, per case (2018 dollars) Multidrug-resistant (MDR) tuberculosis disease is a major health threat globally. Nearly half a million MDR TB cases are estimated to occur worldwide annually, including cases that are extensively drug-resistant (XDR). effects. However, the number of drug-resistant cases in the United States remains stable due to effective control strategies. TB Treatment: 6–9 months $175,000 $218,000 $544,000 MDR TB Treatment: 20–26 months Treatment: 32 months $49,000$393,000$758,000 Productivity loss during treatment, including deaths HospitalizationStop Working Require Home IsolationDie During Treatment experienced by many patients treated for drug-resistant TB: Hearing ImpairmentVision Impairment HepatitisSeizures Kidney Impairment Depression/PsychosisLoss of Mobility of those treated for drug-resistant TB: MDR AND XDR TB PREVENTABLE AND CONTROLLABLE IN THE U.S. THROUGH: Better treatment options Rapid Improving global TB Multidrug-resistant TB is resistant to at least two of the best and most important anti-TB drugs (isoniazid and rifampin). Extensively drug-resistant TB is resistant to isoniazid and rifampin among rst-line drugs, resistant to any uoroquinolone and at least one second-line injectable drug.Soures: Marks S et al. Treatment Practices, Outcomes, and Costs of Multidrug-resistant and Extensively Drug-resistant Tuberculosis in the United States. Emerg Infect Dis. 2014;20(5); Aslam et al. Number For more information visit www.cdc.gov/nchhstp/newsroom